静脈血栓塞栓症のリスクに対するPCSK9 (プロプロテインコンバーターゼサブチリシン/ケキシン型9) 抑制の効果
Nicholas A Marston1, Yared Gurmu1, Giorgio E M Melloni1
1TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (N.A.M., Y.G., G.E.M.M., B.G., M.L.O., R.P.G., C.T.R., M.S.S.).
Circulation
|April 1, 2020
まとめ
静脈血栓塞栓症 (VTE) のリスクを,特に1年を超えて大幅に低下させる. リポプロテインのレベルと遺伝的リスクスコアは,この治療から最も恩恵を受ける患者を特定します.
科学分野:
- 心血管医学
- 薬理学について
- 遺伝学
背景:
- コレステロール値と静脈血栓塞栓症 (VTE) のリスクとの関連は不明である.
- プロプロテインコンバーターゼサブチリシン/ケキシン型9 (PCSK9) 抑制は,心血管疾患のリスクを管理するための新しい治療戦略です.
研究 の 目的:
- VTEリスクに対するPCSK9阻害の影響を決定する.
- 潜在的メカニズムを調査し,リポプロテイン (a) [Lp (a) ]の役割を含め,VTEリスクの減少を裏付ける.
- 臨床的および遺伝的リスク因子によって定義された特定の患者サブグループにおけるPCSK9抑制の有効性を調べる.
主な方法:
- エボロキュマブのVTE事件への影響を評価するFOURIER試験のポストホック分析.
- FOURIERとODYSSEY OUTCOMES試験のデータを組み合わせたメタ解析で,VTEに対するPCSK9抑制のクラス効果を評価した.
- 発症時の脂質とLp (a) レベルを分析し,VTEポリジェニックリスクスコアを用いた探索的遺伝子分析を行う.
主要な成果:
- FOURIER試験では,エボロキュマブがVTEリスクの低下 (HR,0. 71; P=0. 05) の傾向を示し,1年後に有意な減少が観察されました (HR,0. 54; P=0. 014).
- メタアナリシスは,PCSK9阻害によるVTEの相対リスクの有意な31%の減少を確認した (HR,0. 69; P=0. 007).
- VTEリスクの減少は,ベースラインの脂質タンパク質 (a) [Lp (a) ]レベルと有意に関連しており,遺伝的リスクが高い患者が特定されました.
結論:
- PCSK9の抑制は,静脈血栓塞栓症 (VTE) のリスクを効果的に減らす.
- Lp (a) の減少は,PCSK9抑制で観察されたVTEリスクの減少を媒介する重要なメカニズムである可能性があります.
- 遺伝的リスクの階層化は,VTEの予防のためにPCSK9抑制により大きな利益を得る個人を特定することができます.
関連する概念動画
Venous Thrombosis III: Interprofessional Care
220
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
220
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.9K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.9K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
968
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
968
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.5K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.5K
Venous Thrombosis I: Introduction
201
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
201
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
304
Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
304


